全國(guó)服務(wù)咨詢熱線：
18860915427
18860915427
簡(jiǎn)要描述：GSK269962A(GSK269962) 850664-21-0GSK269962A(GSK269962)是人ROCK1和ROCK2抑制劑，IC50分別為1.6和4 nM，比對(duì)其它絲an酸/蘇an酸激酶的抑制性強(qiáng)30倍。
產(chǎn)品型號(hào)：abs812025廠商性質(zhì)：生產(chǎn)廠家更新時(shí)間：2026-02-24訪 問 量：1802產(chǎn)品分類
Product Category詳細(xì)介紹
| 品牌 | absin | CAS | 850664-21-0 |
|---|---|---|---|
| 分子式 | C29H30N8O5 | 純度 | ＞98% |
| 分子量 | 570.6 | 貨號(hào) | abs812025 |
| 規(guī)格 | 10mg | 供貨周期 | 現(xiàn)貨 |
| 主要用途 | 是人ROCK1和ROCK2抑制劑 | 應(yīng)用領(lǐng)域 | 化工,生物產(chǎn)業(yè),農(nóng)林牧漁,制藥/生物制藥,綜合 |
GSK269962A(GSK269962) 850664-21-0
| 產(chǎn)品描述 | |
| 描述 | GSK269962A(GSK269962)是人ROCK1和ROCK2抑制劑，IC50分別為1.6和4 nM，比對(duì)其它絲an酸/蘇an酸激酶的抑制性強(qiáng)30倍。 |
| 純度 | ＞98% |
| 儲(chǔ)存/保存方法 | Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution. |
| 基本信息 | |
| 別名 | GSK 269962A；GSK-269962A；GSK269962；GSK 269962；GSK-269962 |
| 外觀 | powder |
| 可溶性/溶解性 | DMSO : ≥ 30 mg/mL (52.58 mM) |
| 生物活性 | |
| 靶點(diǎn) | ROCK1,ROCK2,RSK1,MSK1,AKT1,AKT2,AKT3 |
| In vitro(體外研究) | GSK269962A IC50 values of 1.6 nM toward recombinant human ROCK1. GSK269962A also exhibits more than 30-fold selectivity against a panel of serine/threonine kinases. GSK269962A induces vasorelaxation in preconstricted rat aorta with an IC50 of 35 nM. Both are highly potent toward human ROCK1 with IC50 of 1.6 nM for GSK269962A. On the other hand, GSK269962A has a significantly improved kinase selectivity profile with at least >30-fold selectivity against the panel of protein kinase tested. |
| In vivo(體內(nèi)研究) | Oral administration of GSK269965A (0.3, 1, and 3 mg/kg) induces a dose-dependent reduction in blood pressure in spontaneously hypertensive rat (SHR). The reduction of blood pressure is acute and substantial. The maximal effect on blood pressure is observed approximately 2 h after oral gavages for both compounds. Under a similar setting, oral administration of Y-27632 (10 and 30 mg/kg) also induced a dose-dependent decrease of blood pressure. For all three Rho kinase inhibitors, the reduction of blood pressure is accompanied by an acute, dose-dependent increase in heart rate, presumably due to the activation of baroreflex mechanism. |
| 研究領(lǐng)域 | |
| 研究領(lǐng)域 | CancerCell cycleCell division Cell CycleCell DivisionCentromere Signal TransductionCytoskeleton / ECMCytoskeletonMicrofilamentsActin etcActin Assembly Signal TransductionProtein PhosphorylationSer / Thr KinasesOther Kinases Drug DiscoverySmall Molecule DrugLead Compound Discovery |
產(chǎn)品咨詢
地址：上海市浦東新區(qū)新浩路58號(hào)申江科創(chuàng)園18棟
郵箱：fengmj@univ-bio.com
傳真：
電話
微信掃一掃